Bispecific & multispecific antibodies
Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient's own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.
therapeutics-platforms
7 min